Medizinische Hochschule Hannover;Twincore, Zentrum Für Experimentelle und Klinische Infektionsforschung GMBH;Helmholtz-Zentrum Für Infektionsforschung GMBH
发明人:
Mark Brönstrup,Hans-Peter Prochnow,N.V. Suryanarayana Birudukota,Thomas Schulz,Martin Messerle,Thomas Pietschmann,Sibylle Haid,Sebastian Blockus,Christine Laqmani-Goffinet,Sergej Franz,Dominic Howard
申请号：
US16665956
公开号：
US20200093888A1
申请日:
2019.10.28
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV； FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g. for treating an infectious disease caused by an infection with RSV, KSHV, CMV, DENV, CHIKV, TBEV, VSV, ZIKV and/or HCV.
